Union Health Ministry Proposes Amendment to New Drugs and Clinical Trials Rules, 2019 to Bring Antimicrobials under Central Regulatory Oversight
FlashcardsQuick reviseKey facts. One by one.Start →In this note
- At a Glance
- Why in the News
- Background & Evolution
- Core Static Facts
- Multi-Dimensional Analysis
- Recent Developments (last 12–18 months)
- Prelims Hooks
- The FDC Story: A 'New Drug' Label Has Not Stopped States Before
- Checking a Product at Licensing Does Not Catch Bad Batches Later
- Is a Central Gate Really Better? The States' Case, Answered
- Anchors for Answers
- Mains Relevance
- Related Topics to Study Next
- NCERT Concepts to Revise
- Common Errors / Trap Areas
1. At a Glance
- The Union Ministry of Health and Family Welfare has issued a draft notification. It would add antimicrobials to the definition of "New Drug" in the New Drugs and Clinical Trials (NDCT) Rules, 2019, so they face stricter scrutiny before licensing [1].
- The goal is to curb antimicrobial resistance (AMR). Substandard or ineffective antimicrobials can help AMR develop and spread, which puts patient safety at risk [1].
- Under the change, a manufacturer must get Central Licensing Authority (CLA) permission first. Only then can it apply to the State Licensing Authority (SLA) for a manufacturing licence. This strengthens central oversight [1].
- For UPSC, the topic links health regulation, federalism in drug licensing, delegated legislation and global AMR governance (One Health).
2. Why in the News
- The Health Ministry published Draft Gazette Notification G.S.R. 983 (E), dated 6 November, proposing to amend Rule 2(1)(w)(v) of the NDCT Rules, 2019 [1].
- Stakeholders and the public can file objections and suggestions within 30 days of the Gazette copies being made available. The Central Government will consider finalising the rule after that [1].
- The stated reason is that manufacturing licences for antimicrobials were being granted without adequate scrutiny, including bioavailability/bioequivalence (BA/BE) and stability studies. Without these, quality, safety and efficacy can suffer [1].
3. Background & Evolution
- 2019: The NDCT Rules, 2019 were framed as the framework for new drugs [1].
- 2023 (G20, India's presidency): The G20 New Delhi Leaders' Declaration stressed tackling AMR through a One Health approach [1]. The year and the presidency are general knowledge, not stated in the source digest.
- 26 Sep 2024: The UN General Assembly adopted a Political Declaration on AMR at the second UN High-Level Meeting on AMR [2][3].
- May 2025 (WHA78): The WHO Director-General's report to the World Health Assembly gave updated AMR burden estimates [5].
- 6 Nov (current draft): G.S.R. 983 (E) proposed adding antimicrobials to the "New Drug" definition [1].
- Related Indian initiatives (no whitelisted source retrieved, so no facts are cited here): National Policy for Containment of AMR, National Action Plan on AMR (NAP-AMR) and NAP-AMR 2.0, and the "Red Line" campaign.
4. Core Static Facts
| Item | Fact |
|---|---|
| Instrument amended | New Drugs and Clinical Trials Rules, 2019 [1] |
| Clause amended | Rule 2(1)(w)(v), the definition of "New Drug" [1] |
| Draft notification | G.S.R. 983 (E), dated 6 November [1] |
| Ministry | Union Ministry of Health and Family Welfare [1] |
| Consultation window | 30 days from public availability of Gazette copies [1] |
| Licensing sequence | CLA prior permission → SLA manufacturing licence [1] |
| Scrutiny named | BA/BE studies, stability studies [1] |
| Parameters protected | Quality, safety, efficacy [1] |
| Global framing | One Health, as in the G20 New Delhi Leaders' Declaration [1] |
| UNGA AMR target | Cut deaths from bacterial AMR by 10% by 2030 from a 2019 baseline of 4.95 million deaths [3] |
| Global coordination | Quadripartite Joint Secretariat on AMR is the central coordinating mechanism [3] |
| Surveillance | Countries encouraged to report AMR and antimicrobial-use data by 2030 through GLASS (WHO) [3] |
| Burden (WHO) | About 4.71 million deaths associated with AMR in 2021, of which 1.14 million were directly attributable [5] |
- Definition: AMR means microbes become resistant to the drugs meant to treat them. It is a major global public health concern that needs coordinated action [1].
- Not in the whitelisted sources (verify before relying on these): the NDCT Rules are framed under the Drugs and Cosmetics Act, 1940, and the CLA is the Drugs Controller General of India (DCGI), who heads the CDSCO.
5. Multi-Dimensional Analysis
Legal / Constitutional
- This is a change to delegated legislation: rules amended by Gazette notification, not by an Act of Parliament [1].
- It works by pulling antimicrobials into an existing legal category ("New Drug") rather than writing a new regulatory regime [1].
- The draft → objections → final notification sequence is a participatory safeguard in rule-making [1].
Administrative / Federal
- It adds a central gate (CLA) before the state licence (SLA). This shifts effective control toward the Centre in an area where states have traditionally issued manufacturing licences [1].
- The trade-off is better uniformity in quality checks against more approval load and possible delays at the central level.
Scientific / Technological
- BA/BE studies check that a generic delivers the active ingredient comparably to the reference product. Stability studies check that potency holds over shelf life [1].
- Under-dosing from a substandard antimicrobial exposes microbes to sub-lethal drug levels, which selects for resistance. This is the scientific basis for the link the ministry draws [1].
Social / Public Health
- Ineffective antimicrobials put patient safety at risk [1]. Patients who rely on low-cost generics are the most exposed to quality failures.
- Global burden: about 4.71 million AMR-associated deaths in 2021 [5].
Economic
- Compliance costs (BA/BE and stability studies) may weigh on small and medium manufacturers and could consolidate the market.
- Over time, credible quality control supports India's standing as a generics exporter.
Geopolitical / Governance
- The move fits India's G20 commitment to One Health [1] and the UNGA 2024 targets, which include a 10% cut in deaths by 2030 [3].
6. Recent Developments (last 12–18 months)
- 6 Nov: Draft G.S.R. 983 (E) issued, with a 30-day comment window [1].
- May 2025 (WHA78): The WHO DG report put AMR-associated deaths at 4.71 million in 2021 [5]. This is just outside the 18-month window.
- Earlier context: the 26 Sep 2024 UNGA Political Declaration on AMR [2][3].
- No whitelisted source was retrieved for other domestic steps in this period (for example, NAP-AMR 2.0 or CDSCO advisory-body recommendations), so they are not listed here.
7. Prelims Hooks
- The draft amends Rule 2(1)(w)(v) of the NDCT Rules, 2019 [1].
- The draft notification number is G.S.R. 983 (E) [1].
- Ministry: Health and Family Welfare, not Chemicals and Fertilizers [1].
- The objection window is 30 days from public availability of the Gazette copies [1].
- Sequence: CLA permission first, then the SLA manufacturing licence [1].
- Studies named: bioavailability/bioequivalence and stability studies [1].
- The G20 New Delhi Leaders' Declaration stressed AMR through One Health [1].
- The UNGA Political Declaration on AMR was adopted on 26 September 2024 [2][3].
- UNGA target: 10% cut in bacterial AMR deaths by 2030 [3].
- The baseline year is 2019, with 4.95 million associated deaths [3].
- The Quadripartite Joint Secretariat is the central coordinating mechanism for AMR [3].
- GLASS is WHO's Global Antimicrobial Resistance and Use Surveillance System [3].
- WHO estimate for 2021: 4.71 million associated and 1.14 million attributable AMR deaths [5].
8. The FDC Story: A 'New Drug' Label Has Not Stopped States Before
- This route has been tried before, with fixed-dose combinations
- An FDC (fixed-dose combination) is two or more drugs in one pill. FDCs already count as "new drugs", so they already needed central approval first.
- Even so, some State Licensing Authorities gave out manufacturing licences for many FDCs without the approval of the DCGI (Drugs Controller General of India) [8].
-
To clean this up, the Ministry set up an expert committee under Prof. C. K. Kokate in September 2014. CDSCO received about 6,320 applications from manufacturers asking to prove their FDCs were safe and worked [8].
-
Fixing it afterwards took years and was fought in court
- 344 FDCs were banned in March 2016. Companies then filed writ petitions against the ban in several High Courts [9].
- 328 more were banned in September 2018 [8].
-
In June 2026 the Ministry banned 16 more FDCs, including some made with antibiotics. It used Section 26A of the Drugs and Cosmetics Act, 1940 (the Centre's power to ban a drug in the public interest), after the Supreme Court ordered a full review [16].
-
What this means for the draft rule
- Putting antimicrobials under "New Drug" makes CLA permission a legal requirement [1]. The FDC story shows that a legal requirement alone did not stop states from skipping the central step.
-
Every licence given without that permission later needed a ban, a court case or a review, and these cleanups ran for more than ten years.
-
What the Centre should do along with the rule
- CDSCO should check every new state licence for an antimicrobial against a central permission granted earlier. Catching a skipped step on day one is cheaper than running another Kokate-style cleanup.
9. Checking a Product at Licensing Does Not Catch Bad Batches Later
- The draft acts only at the licensing stage
- BA/BE and stability studies are checked once, before the licence is given [1]. They show that the product design works.
-
They do not show that every batch made in later years is good. A factory can make good samples for approval and then cut corners in regular production.
-
Most bad medicine is found after it is already on sale
- In a national survey of 47,012 samples (2014–16), 3.16% were NSQ (Not of Standard Quality: a real product that fails a quality test). Only 13 samples were spurious, meaning fake [15].
- In FY 2025–26, CDSCO labs received 16,548 samples and declared 1,014 of them NSQ [14]. That is about 6% (our own calculation).
-
So the bigger problem is real factories making poor batches, not fake medicines. A licence check does not catch these batches.
-
Antibiotics are among the worst affected around the world
- WHO puts the failure rate at 10.5% for medical products in low- and middle-income countries. This is based on about 48,000 samples from 88 countries [12].
-
Antibiotics and anti-malarials are among the substandard products reported most often [12].
-
How a weak antibiotic leads to resistance
- A weak antibiotic gives the patient too small a dose. This helps resistant microbes survive [13].
-
When the first drug fails, doctors move to second-line drugs (stronger, costlier back-up drugs). Resistance then starts building against those too [13].
-
Today's response comes after the harm
- When a sample fails, the firm is told to recall the batch, and CDSCO publishes monthly drug alerts [17].
-
By then, patients have often already taken that batch.
-
CDSCO and state drug controllers should target antimicrobials in market testing
- Antimicrobials should get extra testing of samples taken from shops, so the licence check is followed by checks on what patients actually buy.
10. Is a Central Gate Really Better? The States' Case, Answered
- The strongest objection: the Centre's own record is weak
- In 2012, the Parliamentary Standing Committee on Health found that 31 new drugs were approved between 2008 and 2010 without clinical trials on Indian patients [10].
- When asked for PSURs (Periodic Safety Update Reports: safety reports a company must file after a drug goes on sale) for 42 drugs picked at random, the Ministry could give them for only 8 [10].
-
So states can fairly ask: why would a gate run by CDSCO do better than state regulators?
-
The answer: the problem it fixes is uneven rules, and that problem is real
- A Rajya Sabha committee on the Drugs and Cosmetics (Amendment) Bill, 2007 found that a major enforcement problem was that licensing was not uniform between the Centre and the States [11].
- The same committee said the belief that state control works better is "far removed from the ground realities" in most States [11].
-
The FDC licences that states gave without DCGI approval prove this in practice [8].
-
What the objection gets right
- A central gate is only as good as the people running it. The 2012 committee report also looked at CDSCO's structure and staff strength [10].
-
If CDSCO gets many more antimicrobial applications without more staff, the result could be slow approvals with no better checks.
-
Balanced view for an answer
- The draft does not abolish state licensing. The SLA still gives the licence [1]. It adds one check that works the same way in every state.
- It will help only if CDSCO gets the capacity that the 2012 committee looked at, and keeps the post-sale safety reporting it was faulted for missing.
11. Anchors for Answers
- Data: WHO found a 10.5% failure rate for medical products in low- and middle-income countries, with antibiotics among the most reported [12]
- Data: 1,014 of 16,548 samples declared NSQ in CDSCO labs, FY 2025–26 [14]. The 2014–16 national survey found 3.16% NSQ and just 13 spurious samples out of 47,012 [15]
- Report/Committee: Kokate Committee (2014), which reviewed FDCs that states had licensed without DCGI approval [8]
- Report/Committee: Parliamentary Standing Committee on Health report on CDSCO (2012): 31 drugs approved without Indian trials, PSURs for only 8 of 42 drugs [10]
- Report/Committee: Rajya Sabha committee on the Drugs and Cosmetics (Amendment) Bill, 2007: licensing not uniform between the Centre and the States [11]
- Law/Case: Section 26A, Drugs and Cosmetics Act, 1940, used to ban 16 FDCs (including some made with antibiotics) in June 2026 after Supreme Court directions [16]. Rule 2(1)(w)(v), NDCT Rules, 2019 [1]
12. Mains Relevance
- GS-II: Health; government policies and interventions; issues in the design of regulatory bodies; Centre–State relations.
- GS-III: Science and technology (biotechnology, pharmaceutical quality); disaster or emerging threats (AMR as a "silent pandemic").
- Question stems: 1. "Substandard drugs are as much a driver of antimicrobial resistance as irrational use." Examine this in light of the proposed amendment to the NDCT Rules, 2019. (15 marks) 2. Discuss the implications of making central permission a precondition for state manufacturing licences for antimicrobials, for drug regulation and cooperative federalism. (10 marks) 3. What is the One Health approach? Evaluate India's regulatory and policy response to AMR against its international commitments. (15 marks)
13. Related Topics to Study Next
- Drugs and Cosmetics Act, 1940 and CDSCO/DCGI: the parent statute and the central regulator behind the CLA.
- National Action Plan on AMR (NAP-AMR / NAP-AMR 2.0): India's main AMR policy framework.
- Schedule H1 and the "Red Line" campaign: existing controls on antibiotic sales and public awareness.
- One Health and the Quadripartite (WHO, FAO, UNEP, WOAH): the global governance architecture [3].
- WHO GLASS and the AWaRe classification: surveillance and antibiotic stewardship tools.
- Antibiotics in veterinary use and aquaculture (e.g., colistin restrictions): the animal-health side of AMR.
- Pharmaceutical quality and the revised Schedule M (GMP): manufacturing standards and India's export credibility.
- Delegated legislation and parliamentary scrutiny: how Gazette rule-making works.
14. NCERT Concepts to Revise
- New Drugs and Clinical Trials Rules, 2019 (Economy): The draft amends this rule set's definition of 'New Drug', which is the core of the article.
- Antimicrobial resistance (Geography): Curbing resistance is the stated goal, and substandard antimicrobials are the link the Ministry draws.
- Drugs and Cosmetics Act, 1940 (Polity): The parent law behind the NDCT Rules and the Section 26A power used to ban FDCs.
- Central Drugs Standard Control Organisation (Polity): CDSCO under the DCGI is the Central Licensing Authority whose prior permission becomes compulsory.
- Delegated legislation (Polity): The change is made by amending rules through a Gazette notification, not by an Act of Parliament.
- Centre-state relations (Polity): Adding a central permission step before state manufacturing licences shifts control between Centre and States.
- Cooperative federalism (Polity): A likely Mains angle: does a central gate on state licensing fit cooperative federalism?
- One Health (Geography): The G20 and UN approach to AMR that links human, animal and environmental health.
- National Action Plan on AMR (Economy): India's main policy framework on AMR, which this regulatory move supports.
- Schedule M (Economy): Manufacturing quality standards (GMP) that complement licensing checks on drug quality.
- Drugs Rules, 1945 (Polity): The older rules where state licensing of drug manufacture sits; the draft changes the NDCT Rules, not these.
- World Health Organization (Polity): WHO supplies the AMR burden data, the GLASS surveillance system and the substandard-drug estimates cited in the note.
15. Common Errors / Trap Areas
- Draft vs final: this is only a draft that invites comments. It is not yet in force [1].
- Which rules: the amendment is to the NDCT Rules, 2019, not the Drugs Rules, 1945, and not an amendment to the Act itself [1].
- CLA vs SLA roles: the CLA gives prior permission and the SLA issues the manufacturing licence. The proposal does not abolish state licensing [1].
- UNGA target wording: the 10% cut by 2030 applies to deaths from bacterial AMR, against a 2019 baseline, not 2021 [3].
- "Associated" vs "attributable" deaths: 4.71 million associated versus 1.14 million attributable in 2021 [5].
Sources
- 1Press Release Page, Press Information Bureau (MoHFW draft amendment to NDCT Rules, 2019):pib.gov.in · tier 1
- 2WHO, "World leaders commit to decisive action on antimicrobial resistance" (26 Sep 2024):who.int · tier 2
- 3UN Meetings Coverage, "General Assembly Adopts Political Declaration on Antimicrobial Resistance" (GA/12642):press.un.org · tier 2
- 4UN PGA, AMR Political Declaration (final text, pre-adoption version "under silence"):un.org · tier 2
- 5WHO, WHA78 Director-General report A78/8:apps.who.int · tier 2
- 6comes from the PIB digest you supplied. It gives the draft's date only as "6 November", with no year.
- 7to [S5] facts come from search-result summaries; I did not fetch those pages in full. [S4] is the pre-adoption draft text, and it is not cited for any specific fact in the note.
- 8Prohibition and restriction of manufacture, sale and distribution of Fixed Dose Combinations (FDCs)pib.gov.in · tier 1
- 9Banning of FDC Drugspib.gov.in · tier 1
- 10Lapses in the process of drug approval in India (PRS blog)prsindia.org · tier 1
- 11Rajya Sabha Department-related Parliamentary Standing Committee report on the Drugs and Cosmetics (Amendment) Bill, 2007prsindia.org · tier 1
- 121 in 10 medical products in developing countries is substandard or falsifiedwho.int · tier 2
- 13Brief: Antimicrobial resistance and primary health carewho.int · tier 2
- 14Ministry of Health & Family Welfare Initiatives & Achievements-2025static.pib.gov.in · tier 1
- 15Health Ministry undertakes largest ever drug survey in the world for determining the quality of drugspib.gov.in · tier 1
- 16Union Ministry of Health and Family Welfare Prohibits Manufacture, Sale and Distribution of 16 Fixed Dose Combinations (FDCs) in Public Interestpib.gov.in · tier 1
- 17Status of Drug Quality Testing under CDSCOpib.gov.in · tier 1